Bicycle Therapeutics IPO raised $60.6 million. Bicycle priced its offering of approximately 4.4 million shares at $14 apiece, which was the low end of its targeted price range. Bicycle, which is based in Cambridge, UK, and has US operations in Lexington, MA, is developing drugs based on chains of amino acids called peptides. Peptide drugs are intended to offer properties of both large and small molecule drugs. The company, calls its drugs “bicycles,” a reference to the two-loop shape of its peptides. Source: Xconomy 23/5/2019